Standout Papers

Incorporation of Bevacizu... 2001 2026 2009 2017 2011 2003 2001 2002 2014 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
    2011 1.6k citations Robert A. Burger, Mark F. Brady et al. New England Journal of Medicine profile →
  2. Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer
    2003 921 citations I. Craig Henderson, Donald A. Berry et al. Journal of Clinical Oncology profile →
  3. Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology*
    2001 616 citations Abram Recht, Stephen B. Edge et al. Journal of Clinical Oncology profile →
  4. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
    2002 520 citations Lalitha Iyer, Soma Das et al. The Pharmacogenomics Journal profile →
  5. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
    2014 445 citations Joyce F. Liu, William T. Barry et al. The Lancet Oncology profile →
  6. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors
    2018 430 citations Jason J. Luke, Jeffrey M. Lemons et al. Journal of Clinical Oncology profile →
  7. Current recommendations and recent progress in endometrial cancer
    2019 420 citations Rebecca Brooks, Gini F. Fleming et al. CA A Cancer Journal for Clinicians profile →
  8. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
    2019 370 citations Kathleen N. Moore, Angeles Alvarez Secord et al. The Lancet Oncology profile →

Immediate Impact

3 by Nobel laureates 6 from Science/Nature 69 hit
Sub-graph 1 of 16

Citing Papers

Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
2020 Hit
Endometrial Cancer
2020 Hit
21 intermediate papers

Works of Gini F. Fleming being referenced

Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)
2020
The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: A Gynecologic Oncology Group study
2007
and 14 more

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Gini F. Fleming 8.1k 5.4k 4.1k 3.7k 3.2k 330 16.5k
Jonathan A. Ledermann 9.1k 1.1× 8.0k 1.5× 4.9k 1.2× 2.2k 0.6× 2.7k 0.9× 295 17.3k
Amit M. Oza 10.7k 1.3× 7.0k 1.3× 7.4k 1.8× 3.5k 0.9× 2.3k 0.7× 596 21.6k
Andrew Berchuck 5.8k 0.7× 6.9k 1.3× 8.1k 2.0× 3.8k 1.0× 4.0k 1.3× 358 19.8k
Maurie Markman 6.4k 0.8× 7.8k 1.5× 4.3k 1.0× 2.7k 0.7× 2.7k 0.8× 418 19.9k
Gabriella Ferrandina 4.8k 0.6× 5.7k 1.1× 4.6k 1.1× 2.0k 0.5× 4.6k 1.4× 497 15.7k
Isabelle Ray‐Coquard 6.9k 0.8× 5.0k 0.9× 2.8k 0.7× 1.7k 0.5× 2.0k 0.6× 416 16.0k
Carol Aghajanian 6.1k 0.7× 7.4k 1.4× 3.6k 0.9× 1.4k 0.4× 4.2k 1.3× 424 15.2k
Karen H. Lu 6.8k 0.8× 8.3k 1.5× 7.4k 1.8× 4.7k 1.3× 5.2k 1.6× 430 21.5k
Douglas A. Levine 6.7k 0.8× 7.3k 1.4× 9.2k 2.2× 6.2k 1.7× 4.5k 1.4× 256 22.3k
Ursula A. Matulonis 13.3k 1.6× 8.2k 1.5× 7.9k 1.9× 3.1k 0.8× 2.0k 0.6× 439 23.0k

All Works

Loading papers...

Rankless by CCL
2026